Prevalence and risk factors of disability and anxiety in a retrospective cohort of 432 survivors of Coronavirus Disease-2019 (Covid-19) from China

Siyi Zhu[1,2,¶]; Qiang Gao[1,2,¶]; Lin Yang [1,2,¶]; Yonghong Yang[1,2,¶]; Wenguang Xia[4]; Xiguo Cai[5]; Yanping Hui[6]; Di Zhu[7]; Yanyan Zhang[8]; Guiqing Zhang[9]; Shuang Wu[10]; Yiliang Wang[11]; Zhiqiang Zhou[12]; Hongfei Liu[13]; Changjie Zhang[14]; Bo Zhang[15]; Jianrong Yang[16]; Mei Feng[3]; Zhong Ni[3]; Baoyu Chen[1]; Chunping Du[1,2]; Hongchen He[1,2]; Yun Qu[1,2]; Quan Wei[1,2]; Chengqi He[1,2,17,¶*]; Jan D. Reinhardt[17,18,19,20,¶*].

[1] Rehabilitation Medical Center, West China Hospital, Sichuan University, Chengdu, China.

[2] Rehabilitation Medicine Key Laboratory of Sichuan Province, Sichuan University, Chengdu, China.

[3] Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.

[4] Hubei Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan, Hubei, China.

[5] Henan Provincial People’s Hospital, Zhengzhou, Henan, China.

[6] The Second Affiliated Hospital, Medical College of Xi'an Jiaotong University, Xian, Shanxi, China.

[7] Zhejiang provincial People's Hospital, Hangzhou, Zhejiang, China.

[8] Qilu Hospital of Shandong University, Jinan, Shandong, China.

[9] The First Affiliated Hospital, School of Medicine, Shihezi University, Xinjiang, China.

[10] The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.

[11] Chongqing Three Gorges Central Hospital, Chongqing, China.

[12] Inner Mongolia Autonomous Region Baotou Central Hospital, Baotou, China.

[13] General Hospital of General Bureau of Agricultural Reclamation of Heilongjiang Province, Harbin, China.

[14] The Second Xiangya Hospital of Central South University, Changsha, China.

[15] Nanchong central hospital, Nanchong, Sichuan, China.

[16] Garze People's Hospital, Garze Tibetan Autonomous Prefecture, Sichuan, China.

[17] Institute for Disaster Management and Reconstruction of Sichuan University and Hong Kong Polytechnic University, Sichuan University, Chengdu, China.

[18] Swiss Paraplegic Research, Switzerland.

[19] Department of Health Sciences and Medicine, University of Lucerne, Switzerland.

[20] Committee for Rehabilitation Disaster Relief, International Society for Physical and Rehabilitation Medicine, Geneva, Switzerland.

¶S Zhu, Q Gao, L Yang, Y Yang, Q Wang, C He and JD Reinhardt contributed equally and share first authorship.

[*]Correspondence to: Prof Chengqi He MD, Rehabilitation Medical Center, West China Hospital, No.37 Guoxue Alley, Wuhou District, Chengdu, China **hxkfhcq@126.com**

or Prof Jan D. Reinhardt PhD, Institute for Disaster Management and Reconstruction of Sichuan University and Hong Kong Polytechnic University, Sichuan University, 122 Huanghe Zhong Lu, Chengdu 610041, Sichuan, China **jan.reinhardt@paraplegie.ch**.

Abstract

Objective: To estimate the prevalence of disability and anxiety in Covid-19 survivors at discharge from hospital and analyze relative risk by exposures.

Design: Multi-center retrospective cohort study.

Setting: Twenty-eight hospitals located in eight provinces of China.

Methods: A total of 432 survivors with laboratory-confirmed SARS CoV-2 infection participated in this study. At discharge, we assessed instrumental activities of daily living (IADL) with Lawton's IADL scale, dependence in activities of daily living (ADL) with the Barthel Index, and anxiety with Zung's self-reported anxiety scale. Exposures included comorbidity, smoking, setting (Hubei vs. others), disease severity, symptoms, and length of hospital stay. Other risk factors considered were age, gender, and ethnicity (Han vs. Tibetan).

Results: Prevalence of at least one IADL problem was 36.81% (95% CI: 32.39-41.46). ADL dependence was present in 16.44% (95% CI: 13.23-20.23) and 28.70% (95% CI: 24.63- 33.15) were screened positive for clinical anxiety. Adjusted risk ratio (RR) of IADL limitations (RR 2.48, 95% CI: 1.80-3.40), ADL dependence (RR 2.07, 95% CI 1.15-3.76), and probable clinical anxiety (RR 2.53, 95% CI 1.69-3.79) were consistently elevated in survivors with severe Covid-19. Age was an additional independent risk factor for IADL

limitations and ADL dependence; and setting (Hubei) for IADL limitations and anxiety. Tibetan ethnicity was a protective factor for anxiety but a risk factor for IADL limitations. **Conclusion:** A significant proportion of Covid-19 survivors had disability and anxiety at discharge from hospital. Health systems need to be prepared for an additional burden resulting from rehabilitation needs of Covid-19 survivors.

Keywords: COVID-19; Rehabilitation; Disability; Activities of Daily Living; Mental Health; Anxiety.

Introduction

With rapidly increasing numbers of confirmed cases and deaths caused by the Coronavirus Disease-2019 (Covid-19) pandemic, clinical outcomes research has almost exclusively focused on disease progression and mortality[1]. With the case fatality rate estimated to lie somewhere between 0.56 and 9.38 percent globally (95% prediction interval, I^2 = 100%),[2] it is obvious however that a vast majority of people actually survive Covid-19. A substantial proportion of survivors have experienced severe disease episodes requiring hospitalization and - in a considerable number of cases - intensive care including mechanical ventilation[3]. In addition, contracting a potentially fatal disease is stressful and can cause anxiety and other psychiatric manifestations in many patients.[4] It would be naïve to assume that health problems just disappear upon discharge from acute care or when viral RNA is no longer detectable, and equally naïve to take planned and systematic follow up of patients for granted.[5, 6] Yet, the burden of disease resulting from physical and psychological sequelae of Covid-19 in patients

surviving the disease as well as potential long-term adverse effects from treatments including steroids such as Dexamethasone are just beginning to catch attention[7, 8]. Globally, respiratory infections and tuberculosis assume already the fourth rank of all diseases in terms of disability adjusted life years (DALYs) and the 17th rank in years lived with disability (YLD). In infectious disease, they sadly rank first and second, respectively.[9, 10] Covid-19 will increase this burden considerably and cause longer term mental and physical health problems, work disability, and reduced quality of life in survivors, frontline health professionals, and those quarantined.[11, 12] What we know from the 2002/2003 Severe Acute Respiratory Syndrome (SARS) epidemic is not encouraging. In Hong Kong for example, about 80 percent of SARS survivors still needed follow-up treatment two years after the outbreak had been contained.[13]

The number of patients needing follow-up care and rehabilitation due to Covid-19 will be unprecedented. Countries need to consider and plan for this additional long-term challenge to the health system. It is important to understand risk factors for disability and mental health problems now in order to direct scarce resources and meet windows of opportunity for treatment. This study makes a first attempt to address this issue. We aimed to (1) estimate the prevalence of disability and anxiety in Covid-19 survivors from eight Provinces/centrally governed municipalities of the PR China at discharge from acute inpatient treatment, and (2) investigate relative risk of adverse outcomes by various determinants including gender, age, comorbidity, setting, ethnicity and disease severity. Prevalence estimates are important to gain insight in the potential number of patients needing follow-up care. Analyzing risk factors is instrumental in identifying vulnerable groups and allocating resources for early interventions.

Methods

Study design

We conducted a multi-center retrospective cohort study. The study protocol was approved by the ethics committee of West China Hospital, Sichuan University (2020-273).

Subjects

Four hundred and thirty-two Covid-19 survivors were surveyed who had received treatment in 28 designated hospitals in Hubei, Sichuan, Guizhou, Henan, Neimenggu (inner Mongolia), Shandong, Hainan, and Chongqing from January 18 to March 15, 2020 and gave informed consent. Included were adults (≥ 16 years) who had laboratory-confirmed SARS coronavirus-2 (SARS CoV-2) infection and met the diagnostic criteria of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7) issued by the National Health Commission of the PR China (Third edition).[14] Survivors further needed to be in stable medical condition and have been discharged or be about to be discharged from the participating centers. Excluded were patients with pneumonia caused by other types of coronaviruses, seasonal influenza, bacteria, or other not SARS CoV-2 etiology.

Patients were contacted by health professionals who were in charge of their treatment. All health professionals were instructed on implementation of the study protocol, informed consent procedures, and possible sources of bias by videoconference.

Measures

Outcomes: Outcomes were disability and anxiety. Cut off date for outcome assessment was April 7, 2020. Disability was measured in two ways: (1) Limitations in instrumental activities of daily living (IADL) were assessed with the Lawton IADL scale[15] and

classified into no limitations vs. one or more limitations (primary outcome). An index of the number of reported IADL limitations was also created. (2) Dependence in activities of daily living (ADL) was measured with the Barthel Index[16] and classified into severe or moderate dependence vs. mild dependence/independence.[17] Anxiety was evaluated with Zung's Self-Reported Anxiety Scale[18] (SAS) and classified into probable clinical anxiety disorder vs. not according to a conservative cutoff recommended for research.[19] Outcome data were patient-reported and collected with an online questionnaire.

Risk factors: Clinical and demographic data were extracted from hospital records by participating health professionals. Current smoking status was self-reported by participants. Demographic data included age, gender, province (Hubei vs. others), and ethnicity (Han vs. Tibetan). Having received treatment in Hubei was considered a risk factor because of the particular situation in Hubei which was the epicenter of the epidemic in China representing about 80 percent of confirmed cases. Ethnicity was included as a significant proportion of the sample from Sichuan was from the Tibetan ethnic group, and belonging to a minority ethnic group is known to be associated with health outcomes in other disease. Clinical data included comorbidity, disease severity, symptoms at admission, scope of pneumonia, and length of inpatient stay. Recorded comorbid conditions included COPD, chronic bronchitis, pulmonary fibrosis, hypertension, diabetes, cardiovascular disease, kidney disease, hepatitis, rheumatism, and gout. Degree of Covid-19 severity was classified according to the Chinese standard.[14] Patients were defined as severe cases when they met one of the following criteria at any time during hospitalization: acute respiratory distress, respiratory rate ≥30 breath/min; pulse oxygen saturation (SpO2) ≤93% at rest; arterial blood partial pressure

of oxygen/fraction of inspired oxygen (PaO2/FiO2) ≤300 mmHg (1 mmHg = 0.133 kPa); respiratory failure requiring mechanical ventilation; septic shock; failure of other organs requiring ICU treatment. Symptoms recorded at admission included fever, cough, diarrhea, fatigue and pain. Scope of pneumonia was noted as uni- or bilateral per radiographic findings. Data on length of hospital stay were available for 408 patients (94.44%).

Sample size calculation

Sample size to detect a two-fold relative risk for reporting one or more IADL limitations in the severe disease group as compared to the non-severe group with a power of 80% and alpha error of 5% was estimated under the following assumptions: 0.2 ratio of severe to non severe group (based on patients received at our own center), 15 percent prevalence of outcome in non-severe group. This yielded a minimal sample size of 401 (67 severe, 334 non-severe).

Analysis

Prevalence of limitations in IADL, ADL dependence, and anxiety for the full sample and by disease severity were provided with 95% confidence intervals (CIs) estimated from logistic regression. Risk ratios (RR) and 95% CIs for gender, age group (<= 50, 50-60, > 60 years), province (others vs. Hubei), ethnicity (Han vs. Tibetan), comorbid health conditions (none, one, multiple), disease severity (non-severe vs. severe), symptoms (<=1, >1) at admission, and infection scope (unilateral vs. bilateral) were estimated with log-linear Poisson regression with robust standard errors.[20] Since longer time of being hospitalized could increase anxiety, length of hospital stay was included in the anxiety-model in addition. For each outcome unadjusted RR and RR adjusted for all other

potential risk factors evaluated were provided. Zero-inflated Poisson (ZIP) regression was used to estimate the effect of risk factors on the extent of IADL limitations. ZIP regression assumes that there are two groups in the population from which the data are sampled, one which always has zero counts, and one which may have zero or higher counts. Young people with non-severe disease who have no comorbidity may never develop IADL limitations, while other groups may develop (additional) IADL limitations due to factors associated with disease progression. ZIP regression simultaneously performs logistic and Poisson regression making two types of predictions: (1) prediction of excess zeros assuming a binary dependent variable (no IADL limitations vs. one or more), (2) prediction of the count portion (number of experienced IADL limitations). Predictors included in the logistic part were the following background factors: age group and interaction of age and disease severity, province, ethnicity, smoking, and comorbid conditions. Predictors included in the count part were potential drivers of disease consequences: disease severity, interaction of age and disease severity, symptoms, and infection scope. Vuong's test confirmed fit of the ZIP model.

All analyses were performed with Stata 14 (Stata corporation, Texas, USA).

Results

Demographic and clinical characteristics and prevalence of outcomes of the study participants are provided in Table 1. Median age was 49 (IQR 35-60) and 49% were female. About one third of the study participants were classified as severe cases. Fever, cough, and fatigue were the most common symptoms at admission. A majority had no pre-existing health condition and were non-smokers. Patients with severe Covid-19 were older, were more often from Hubei and belonged to the Han majority, presented with

more symptoms, had more often bilateral pneumonia, and stayed in the hospital for a longer time. More pre-existing health conditions were present in severe cases, but the percentage of smokers was lower. Over one third of Covid-19 survivors had at least one IADL limitation, about 15 percent had at least moderate ADL dependence, and six percent were severely dependent. Probable clinical anxiety disorder was found in about 29 percent of the population. Prevalence of all outcomes was more than four times higher in survivors of severe Covid-19 than in those with non-severe disease.

Table 1. Demographic and Clinical Characteristics of study participants (I) and prevalence of outcomes (II)

I. Demographic and clinical characteristics	**All participants (N=432)**	**By disease severity**	
		non-severe (n=285, 65.97%)	severe (n=147, 34.03%)
Female sex – no./total no. (%)	207/432 (47.92)	138/285 (48.42)	69/147 (46.94)
Age			
Median (IQR) in years	49 (35-60)	45 (32.5-54.5)	57 (47-68)
Distribution – no./total no. (%)			
< 50	218/431 (50.58)	173/284 (60.92)	45/147 (30.61)
50-60	108/431 (25.06)	69/284 (24.30)	39/147 (26.53)
> 60	105/431 (24.36)	42/284 (14.79)	63/147 (42.86)
Province – no./total no. (%)			
Hubei	169/432 (39.12)	73/285 (25.61)	96/147 (65.31)
Sichuan	162/432 (37.50)	144/285 (50.53)	18/147 (12.24)
Chongqing	38/432 (8.80)	29/285 (10.18)	9/147 (6.12)
Henan	30/432 (6.94)	15/285 (5.26)	15/147 (10.20)
Guizhou	24/432 (5.56)	17/285 (5.96)	7/147 (4.76)
Other	9/432 (2.08)	7/285 (2.46)	2/147 (1.36)
Ethnicity – no./total no. (%)			

Han	360/432 (83.33)	220/285 (77.19)	140/147 (95.24)
Tibetan	72/432 (16.67)	65/285 (22.81)	7/147 (4.76)
Smoking history, yes – no./total no. (%)	62/432 (14.35)	46/285 (16.14)	16/147 (10.88)
Pre-existing comorbidity – no./total no. (%)			
none	300/432 (69.44)	226/285 (79.30)	74/147 (50.34)
one	79/432 (18.29)	37/285 (12.98)	42/147 (28.57)
multi	53/432 (12.27)	22/285 (7.72)	31/147 (21.09)
Symptoms on admission – no./total no. (%)			
Fever	249/432 (57.64)	125/285 (43.86)	124/147 (84.35)
Cough	257/432 (59.49)	139/285 (48.77)	118/147 (80.27)
Fatigue	153/432 (35.42)	70/285 (24.56)	83/147 (56.46)
Pain	68/432 (15.74)	40/285 (14.04)	28/147 (19.05)
Diarrhea	46/432 (10.65)	24/285 (8.42)	22/147 (14.97)
Bilateral infection scope[&] - no./total no. (%)	362/432 (83.80)	221/285 (77.54)	141/147 (95.92)
Length of hospital stay[§]			
Median (IQR) in days	18 (12-25)	15 (11-22)	23 (15.5-31.61)
Distribution – no./total no. (%)			
1-14 days	160/408 (39.22)	130/268 (48.51)	30/140 (21.43)
>14 days	248/408 (60.78)	138/268 (51.49)	110/140 (78.57)
Discharge Destination[§] - no./total no. (%)			
Discharged home	278/412 (67.48)	215/269 (79.93)	63/143 (44.06)
Discharged to 14-day quarantine	128/412 (31.07)	52/269 (19.33)	76/143 (53.15)
Referred to other hospital	6/412 (1.46)	2/269 (0.74)	4/143 (2.80)
Mechanical Ventilation– no./total no. (%)			
No	395/411 (96.11)	268/268 (100.00)	127/143 (88.81)

Yes	16/411 (3.89)	0/268 (0.00)	16/143 (11.19)
II. Outcomes*			
Disability, percent (95% CI)			
One or more IADL limitations	36.81 (32.39-41.46)	18.25 (14.18-23.16)	72.79 (65.04-79.37)
Moderate ADL dependence	16.44 (13.23-20.23)	6.32 (4.01-9.80)	36.05 (28.71-44.11)
Severe ADL dependence	5.56 (3.75-8.15)	2.46 (1.17-5.06)	11.56 (7.31-17.82)
Anxiety, percent (95% CI)	28.70 (24.63-33.15)	13.33 (9.86-17.80)	58.50 (50.38-66.19)

[§]Scope of pneumonia as confirmed by radiography. [&]For 24 (5.56%) patients discharge date had not been entered in the data form. *Confidence intervals estimated from logistic regression. CI = confidence interval. IADL = instrumental activities of daily living. ADL = activities of daily living.

Results on risk factors for disability and anxiety are displayed in Fig 1 and 2 (for detailed estimates see S1-3 Tables). Risk ratios for reporting at least one IADL limitation (Fig 1, upper panel) were increased in the older age groups, particularly in survivors aged older than 60 years, in patients from Hubei, and in survivors with severe Covid-19. The adjusted model also showed an elevated relative risk in survivors from the Tibetan ethnic group. Only in unadjusted models was the relative risk of having one or more IADL limitations clearly elevated in survivors with comorbidities, in patients with more symptoms at admission, and in those with bilateral infections. Both in unadjusted and adjusted models, the relative risk for ADL dependence (Fig 1 lower panel) was consistently increased in Covid-19 survivors aged older than 60 years, and in participants with severe disease course and more symptoms. All individual risk ratios

were higher in unadjusted models. Setting, comorbidity, and infection site played a role in unadjusted analysis only.

Fig 1. Disability (IADL limitations and ADL dependence) in relation to potential risk factors. Risk ratios and 95% confidence intervals. Estimated from log-linear Poisson regression with robust standard errors; unadjusted risk ratios are estimated from univariable model for the effect of the respective predictor on the outcome, adjusted risk ratios are estimated from multivariable model containing all potential risk factors. IADL = Instrumental Activities of Daily Living. ADL = Activities of Daily Living.CI=confidence interval. Note: In the case of ADL dependence, the upper limit of the confidence interval for the unadjusted estimate of age > 60 years has been truncated for better readability of the other effects (see S1-3 Tables for details). Adjusted model and unadjusted model for age have been estimated for 431 cases (because of one missing date of birth).

Fig 2. Probable clinical anxiety in relation to potential risk factors. Risk Ratios and 95% confidence intervals. Estimated from log-linear Poisson Regression with robust standard errors; unadjusted risk ratios are estimated from univariable model for the effect of the respective predictor on the outcome, adjusted risk ratios are estimated from multivariable model containing all potential risk factors. The adjusted model has been estimated for 407 cases (because of missing information regarding length of stay for 24 cases and one case with missing date of birth). [&]Unadjusted model estimated for 407 cases (because of missing information regarding length of stay for 24 cases and one case with missing date of birth). CI=confidence interval.

Having severe Covid-19 was the strongest risk factor for probable clinically relevant anxiety, followed by having received treatment in Hubei province (Fig 2). In turn, belonging to the Tibetan group was associated with a largely decreased relative risk of anxiety. There was a trend for an increased relative risk of anxiety in survivors who had stayed in the hospital for more than 14 days. Older age, comorbidity, symptoms, and scope of pneumonia played a role in unadjusted analysis only.

Table 2 show the results of the ZIP regression of the number of IADL limitations on risk factors. Hospitalization in Hubei, Tibetan ethnicity, and multi-comorbidity were associated with lower odds of having a zero count of IADL limitations. For all age groups, odds for having zero IADL limitations were decreased in people with severe Covid-19. This effect became however smaller with increasing age. Disease severity, its interaction with age, and symptoms were associated with a greater number of health problems. The joint effect of age and degree of severity of Covid-19 on the number of IADL limitations from both parts of the model is illustrated in Fig 3. In all age groups having a severe course of Covid-19 was associated with a higher number of self-reported IADL limitations. Point estimates for survivors with non-severe and those with severe disease were however closer in the oldest age group. CIs for the number of IADL limitations in participants with non-severe and those with severe Covid-19 moved closer in both older age groups and overlapped in survivors aged 61 years and older.

Table 2. Results from zero-inflated Poisson regression of number of IADL limitations on potential risk factors (n=431)

I. Excess zeros: Prediction of having no IADL limitation	**OR (95% CI)**	**SE**	**z**
Age			

< 50	1 (reference)		
50-60	0.66 (0.24-1.78)	0.51	-0.82
> 60	0.04 (0.01-0.10)	0.54	-6.19
Disease severity and age group			
non-severe and < 50 years old	1 (reference)		
severe and < 50 years old	0.06 (0.02-0.17)	0.51	-5.43
non-severe and 50-60 years old	1 (reference)		
severe and 50-60 years old	0.11 (0.04-0.32)	0.56	-4.02
non-severe and > 60 years old	1 (reference)		
severe and > 60 years old	0.34 (0.10-1.16)	0.62	-1.72
Province			
Other provinces	1 (reference)		
Hubei	0.09 (0.04-0.19)	0.37	-6.46
Ethnicity			
Han	1 (reference)		
Tibetan	0.16 (0.06-0.41)	0.49	3.78
Smoking history			
no	1 (reference)		
yes	1.78 (0.67-4.75)	0.50	1.15
Comorbid conditions			
none	1 (reference)		
one	0.65 (0.29-1.43)	0.41	-1.08
multi	0.33 (0.12-0.90)	0.51	-2.16
II. Count: Number of IADL limitations	IRR (95% CI)	SE	z
Disease severity (reference: non-severe)			
non severe	1 (reference)		
severe	1.64 (0.97-2.80)	0.45	1.84

Disease severity and age group			
non-severe and < 50 years old	1 (reference)		
non-severe and 50-60 years old	1.76 (0.99-3.15)	0.52	1.92
non-severe and > 60 years old	2.91 (1.78-4.77)	0.73	4.24
severe and < 50 years old	1 (reference)		
severe and 50-60 years old	1.34 (1.03-1.74)	0.18	2.21
severe and > 60 years old	1.65 (1.33-2.05)	0.18	4.52
Symptoms, number			
<= 1	1 (reference)		
>1	1.34 (1.10-1.62)	0.13	2.98
Infection scope			
Unilateral	1 (reference)		
Bilateral	1.19 (0.89-1.61)	0.18	1.16

OR = odds ratio, CI = confidence interval, SE = standard error of coefficient, z = standardized coefficient, IRR = incidence rate ratio, IADL = instrumental activities of daily living.

Fig 3. Effect of the interaction of age and disease severity on the number of predicted IADL problems (triangles) with 95% confidence intervals (capped lines). Estimated from zero-inflated Poisson regression. Predictions are adjusted for other factors in the model. Predictors included in the logistic part (excess zeros) were the following: age group, interaction of age and disease severity, setting (Hubei vs. other province), Tibetan ethnicity (reference: Han), smoking history, and comorbid conditions. Predictors included in the count part were: disease severity, interaction of age and disease severity, symptoms, and infection scope. The model has been estimated for 431 cases (because of one missing date of birth).

Discussion

This retrospective cohort study found a considerable prevalence of functional limitations and dependence as well as anxiety in Covid-19 survivors at about time of discharge from acute inpatient treatment. Disease severity was a major independent risk factor for all outcomes. Age was an additional risk factor for both disability outcomes, and setting (Hubei) for IADL limitations and anxiety. Tibetan ethnicity was a strong protective factor for anxiety but a risk factor for IADL limitations when it was adjusted for covariates. Demographic and clinical characteristics of the study population were comparable to other reports on Covid-19 patients from China [1, 21] with two exceptions: a higher percentage was classified as severe cases and current smoking was more prevalent in the non-severe disease group. An explanation for the higher percentage of severe cases in the present study is that the applied criteria for classifying Covid-19 cases as severe by the National Health Commission of the PR China are more liberal than the criteria for severe community-acquired pneumonia by the American Thoracic Society and Infectious Disease Society of America[22] used by Guan et al.[21] The lower prevalence of smokers in participants with severe disease was unexpected and contradicts previous evidence in this regard.[21] A possible explanation is that current smoking status was self-reported and participants with more severe disease outcomes did not reveal their true smoking status, perhaps for fear of being stigmatized and held responsible for contracting SARS CoV-2 or the severity of Covid-19.

We found a high prevalence of disability and anxiety, particularly in severe cases. Almost three quarters of severe Covid-19 survivors experienced at least one IADL problem and more than one third had at least moderate ADL dependence. The six

percent of the overall sample with severe ADL dependence are of particular concern since severe functional dependence has been a reliable predictor of mortality in populations with other health conditions.[23] No other original study directly investigated disability outcomes related to Covid-19 so far. Follow up studies of SARS and Middle East Respiratory Syndrome (MERS) survivors have however shown that decreased exercise capacity and distance walked, fatigue, sleeping problems, shortness of breath, reduced self-rated health, work disability, and structural damage (e.g. osteonecrosis) from corticosteroids were prevalent in survivors even years after onset of symptoms.[11, 24, 25] In addition, access to health care, quality of services, and employment opportunities of former SARS patients were compromised by enduring stigma[13, 26]. Our findings imply that a large proportion of Covid-19 survivors, particularly those who experienced severe disease episodes are in need of follow up care and rehabilitation services. This proportion may be reduced by the integration of early rehabilitation interventions into acute care[27, 28].

Probable clinical anxiety disorder was found in one third of the overall sample and its prevalence was almost four-fold increased in severe as compared to non-severe cases. Previous studies on mental health in the Covid-19 pandemic have been conducted in the general population[29, 30] and health professionals[31] but not in the patient population. Studies in SARS survivors have however reported highly elevated long-term psychiatric morbidity[32] and demonstrated adverse effects on the mental health of caregivers.[11] Our findings point to the need of psychological counseling during acute care and mental health follow-up in many Covid-19 survivors to mitigate suffering and prevent the manifestation of psychiatric disorders.

Major risk factors for mortality due to Covid-19[1, 33] were also major risk factors of disability: older age and severe disease course both independently increased the relative risk of IADL limitations and ADL dependence. However, comorbidity[34] had an adverse effect on disability outcomes in unadjusted analysis only. Though attenuated, disease severity continued to play a major role when it was adjusted for age, co-morbidity, and other potential confounders demonstrating an additional effect of Covid-19 when other known risk factors for disability were held statistically constant. In all age groups having severe Covid-19 was associated with a higher number of self-reported IADL limitations. For survivors aged over 60 years we found that the extent of IADL limitations was more similar in those with non-severe and severe Covid-19 than in the other age groups. Accordingly, the oldest participants with non-severe Covid-19 were more similar to survivors with severe disease in the younger age groups. There are two possible explanations for this phenomenon that deserve further scrutiny: First, older people have already more activity limitations before they acquire Covid-19. Second, a non-severe disease course has a greater effect on IADL limitations for them. Persistence of this effect when it was adjusted for comorbidity speaks for the latter explanation. Having been treated in hospitals of Hubei province where Covid-19 spread first and overwhelmed an unprepared health system was furthermore associated with adverse disability outcomes, particularly IADL limitations. Moreover, belonging to the Tibetan ethnic minority predicted worse IADL outcomes when it was controlled for other potential risk factors. Given that the Tibetan population of Sichuan province mainly lives in rural, mountainous areas, both findings point at the role that environmental factors including the availability and accessibility of targeted services play in the disablement process.[35] Our findings indicate that priority in rehabilitation resource allocation should

be given to patients with severe disease course, older people, and those living in environments with restricted accessibility of services.

Regarding anxiety, outstanding independent risk factors were severity of Covid-19 and setting, i.e. having been hospitalized in Hubei province. Apart from the specific situation in hospitals in Hubei, insecurity about causes, transmission patterns, and prognosis when Covid-19 first occurred likely contributed to this finding. Moreover, we found a trend for longer length of hospital stay being independently associated with increased relative risk of anxiety. In contrast to disability outcomes, Tibetan ethnicity was a consistent protective factor in unadjusted as well as adjusted models of anxiety. Possible explanations are cultural factors including larger families (due to the non application of China's one child policy to this group) and greater social cohesion and support. This finding needs further exploration. Our results point towards heightened need for psychological support in patients who experienced severe disease episodes and people from areas hardest hit by the Covid-19 pandemic.

Study Limitations

The present study has limitations. First, baseline data for the outcomes analyzed here were not available. Because of this we cannot rule out that patients had disability or anxiety before they contracted Covid-19, indeed having disability may have made people more vulnerable to the disease [36-38]. However, most patients first presented already with severe symptoms and baseline information collected before admission is rare in any disease. Baseline information on comorbidity is thus as close as we get to baseline disability and the effects of disease severity on outcomes remained consistent when adjusted for baseline comorbidity in our analysis. Second, we may be criticized for not having employed some kind of control group. An appropriate control group for the

effects and population under investigation is however difficult to define and to establish. Age and gender matched general population controls are surely not appropriate because of the lack of hospitalization. Investigating patients who have been hospitalized for some other disease would not help disentangle the effects of disease and hospitalization. Quarantined persons suspected for Covid-19 or those treated at home may make up an interesting comparator but are difficult to access. We believe that our comparison of patients with severe and non-severe Covid-19 nonetheless provides initial evidence for the potential impact of the disease and is an important starting point in investigating this population's rehabilitation needs. Third, outcome data were self-reported by patients due to the lack of options for objective measurement. Survivors thus may have under- or overestimated their physical abilities. Patient-reported outcome measures have however not been used in this population before to the best of our knowledge, making it difficult to appraise if and to what degree this kind of problem existed. Fourth, psychiatric confirmation of anxiety in those screened positive was not possible. Fifth, this study evaluated outcomes at discharge and conclusions about longer-term prevalence, spontaneous recovery, and chronic manifestations cannot be drawn at this point and further follow-up of the cohort is therefore indicated.

Recommendations

In spite of these limitations, there are several recommendations that can be derived from our findings. First, awareness about possible functional and psychological consequences of Covid-19 needs to be raised in patients, care providers, and health policy makers[28]. Second, early psychological[39] and pulmonary rehabilitation interventions including mobilization and exercise[27, 28, 40] which have been investigated in other health conditions could be effective and important to meet

therapeutic windows; consequently their application (besides pharmacological treatments) needs to be studied in the population of Covid-19 patients, particularly those with severe disease. Third, this involves a better integration of primary care and psychiatric and rehabilitation services which is unfortunately lacking in many lower as well as higher resourced countries including China.[41] Fourth, systematic community follow up and two-way referral systems between community health centers and specialized hospital units, another weak point of many health systems, need to be strengthened.[41] Fifth, we recommend that future prospective cohort studies in Covid-19 survivors include functional and psychiatric outcomes.

Conclusion

A significant proportion of Covid-19 survivors had disability and anxiety at discharge from hospital. Disease severity was the only independent risk factor with consistent adverse effects on all outcomes. Health systems need to be prepared for an additional long-term burden due to Covid-19. This includes raising awareness about mental and physical health problems of survivors, early interventions, strengthening medical follow up, and increasing physical and psychological rehabilitation capacity**.**

Author contributions

CH, SZ and JR had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. CH, SZ, QG, LY, QW, YY and JR designed the study. WX, XC, YH, DZ, YZ, GZ, SW, YW, ZZ, HL, CZ, BZ, JY, MF, ZN, BC, CD, and HH collected and processed the data. JR, SZ, QG, CH, and YY interpreted the data. JR performed the statistical analysis and wrote the first draft of the

manuscript. All other authors revised the manuscript for critical content. All authors reviewed and approved the final submitted version.

Acknowledgment

We thank all the hospital staff members and coordinators under the CSPRM Covid-19 network for their efforts in collecting the information that was used in this study; Liangjiang Huang (Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology), Xu Qin (No.3 People's Hospital of Chengdu), Minqing Li (Dazhou Central Hospital), Kehui Hu (Suining Central Hospital) ,and Jinling Zhang (West China Second University Hospital, Sichuan University) for their dedication to data entry and verification; Prof. Deying Kang (Epidemiologist, West China Hospital, Sichuan University) and Mrs. Rouyue Fang (Statistician, Industrial and Commercial Bank of China) for their assistance in initial data extraction and processing; all the patients who consented to provide their data for analysis and the medical staff members who are at the frontline caring for patients with Covid-19. We would like to thank Prof. Dr. Gerold Stucki and Cristiana Baffone for constructive comments on an earlier version of the manuscript.

Funding

This study was funded by the National Natural Science Foundation (81972146), the Department of Science and Technology of Sichuan Province (20YYJC3320), China Postdoctoral Science Foundation (2020M673251), Health Commission of Sichuan Province (20PJ034), and West China Hospital of Sichuan University (HX-2019-nCoV-011 to Chengqi He, and 2019HXBH058 to Siyi Zhu). The funders played no role in the design, conduct, or reporting of this study.

Competing interests

The authors declare that they have no competing interests.

References

1. Liang W-h, Guan W-j, Li C-c, Li Y-m, Liang H-r, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. European Respiratory Journal. 2020;55(6).

2. Center for Evidence Based Medicine (CEBM). Global Covid-19 Case Fatality Rates (last updated on June 6 2020) 2020 [cited 2020 Aug 10]. Available from: https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/.

3. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020.

4. Tucci V, Moukaddam N, Meadows J, Shah S, Galwankar SC, Kapur GB. The Forgotten Plague: Psychiatric Manifestations of Ebola, Zika, and Emerging Infectious Diseases. Journal of global infectious diseases. 2017;9(4):151-6. Epub 2018/01/06. doi: 10.4103/jgid.jgid_66_17. PubMed PMID: 29302150; PubMed Central PMCID: PMC5750439.

5. Griffiths J, Hatch RA, Bishop J, Morgan K, Jenkinson C, Cuthbertson BH, et al. An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: a 12-month follow-up study. Crit Care.

471 2013;17(3):R100. Epub 2013/05/30. doi: 10.1186/cc12745. PubMed PMID: 23714692; PubMed
472 Central PMCID: PMC3706775.
473 6. Wunderink RG, Waterer G. Advances in the causes and management of community
474 acquired pneumonia in adults. BMJ. 2017;358:j2471. Epub 2017/07/12. doi: 10.1136/bmj.j2471.
475 PubMed PMID: 28694251.
476 7. Fraser E. Long term respiratory complications of covid-19. British Medical Journal
477 Publishing Group; 2020.
478 8. Gonzalez-Jaramillo N, Low N, Franco OH. The double burden of disease of COVID-19 in
479 cardiovascular patients: overlapping conditions could lead to overlapping treatments. European
480 journal of epidemiology. 2020;35(4):335.
481 9. James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and
482 national incidence, prevalence, and years lived with disability for 354 diseases and injuries for
483 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease
484 Study 2017. The Lancet. 2018;392(10159):1789-858.
485 10. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and
486 national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life
487 expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the
488 Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1859-922.
489 11. Tansey CM, Louie M, Loeb M, Gold WL, Muller MP, de Jager J, et al. One-year outcomes
490 and health care utilization in survivors of severe acute respiratory syndrome. Archives of
491 internal medicine. 2007;167(12):1312-20.

492 12. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The
493 psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet.
494 2020. Epub 2020/03/01. doi: 10.1016/S0140-6736(20)30460-8. PubMed PMID: 32112714.
495 13. Siu JY. The SARS-associated stigma of SARS victims in the post-SARS era of Hong Kong.
496 Qualitative health research. 2008;18(6):729-38. Epub 2008/05/27. doi:
497 10.1177/1049732308318372. PubMed PMID: 18503014.
498 14. National Health Commission of the PR China [国家卫生健康委员会]. Diagnostic criteria
499 of the Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 7) [in
500 Chinese; 关于印发新型冠状病毒肺炎诊疗方案（试行第七版）的通知] 2020 [cited 2020
501 March 25]. Available from:
502 http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
503 15. Tong AY, Man DW. The validation of the Hong Kong Chinese version of the Lawton
504 Instrumental Activities of Daily Living Scale for institutionalized elderly persons. OTJR:
505 Occupation, Participation and Health. 2002;22(4):132-42.
506 16. Wade DT, Hewer RL. Functional abilities after stroke: measurement, natural history and
507 prognosis. Journal of neurology, neurosurgery, and psychiatry. 1987;50(2):177-82. Epub
508 1987/02/01. doi: 10.1136/jnnp.50.2.177. PubMed PMID: 3572432; PubMed Central PMCID:
509 PMC1031489.
510 17. Sze KH, Wong E, Or KH, Lum CM, Woo J. Factors predicting stroke disability at discharge:
511 a study of 793 Chinese. Archives of physical medicine and rehabilitation. 2000;81(7):876-80.
512 Epub 2000/07/15. doi: 10.1053/apmr.2000.6279. PubMed PMID: 10895998.

513 18. Zung WW. A Rating Instrument For Anxiety Disorders. Psychosomatics. 1971;12(6):371-
514 9.
515 19. Dunstan DA, Scott N. Norms for Zung's Self-rating Anxiety Scale. BMC psychiatry.
516 2020;20(1):90. Epub 2020/03/01. doi: 10.1186/s12888-019-2427-6. PubMed PMID: 32111187;
517 PubMed Central PMCID: PMC7048044.
518 20. Zou G. A modified poisson regression approach to prospective studies with binary data.
519 American journal of epidemiology. 2004;159(7):702-6.
520 21. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
521 Coronavirus Disease 2019 in China. The New England journal of medicine. 2020. Epub
522 2020/02/29. doi: 10.1056/NEJMoa2002032. PubMed PMID: 32109013.
523 22. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and
524 Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice
525 Guideline of the American Thoracic Society and Infectious Diseases Society of America.
526 American journal of respiratory and critical care medicine. 2019;200(7):e45-e67. Epub
527 2019/10/02. doi: 10.1164/rccm.201908-1581ST. PubMed PMID: 31573350; PubMed Central
528 PMCID: PMC6812437.
529 23. Alger HM, Williams Iv JH, Walchok JG, Bolles MM, Fonarow GC, Rutan C. The Role of Data
530 Registries in the Time of COVID-19. Circulation Cardiovascular quality and outcomes. 2020. Epub
531 2020/04/17. doi: 10.1161/circoutcomes.120.006766. PubMed PMID: 32298145.
532 24. Cao W-C, De Vlas SJ, Richardus JH. The severe acute respiratory syndrome epidemic in
533 mainland China dissected. Infectious disease reports. 2011;3(1).

534 25. Batawi S, Tarazan N, Al-Raddadi R, Al Qasim E, Sindi A, Johni SA, et al. Quality of life
535 reported by survivors after hospitalization for Middle East respiratory syndrome (MERS). Health
536 and quality of life outcomes. 2019;17(1):101.
537 26. Lee S, Chan LY, Chau AM, Kwok KP, Kleinman A. The experience of SARS-related stigma
538 at Amoy Gardens. Soc Sci Med. 2005;61(9):2038-46. Epub 2005/05/26. doi:
539 10.1016/j.socscimed.2005.04.010. PubMed PMID: 15913861.
540 27. Ryrso CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower
541 mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a
542 systematic review and meta-analysis. BMC pulmonary medicine. 2018;18(1):154. Epub
543 2018/09/17. doi: 10.1186/s12890-018-0718-1. PubMed PMID: 30219047; PubMed Central
544 PMCID: PMC6139159.
545 28. Vogiatzis I, Rochester CL, Spruit MA, Troosters T, Clini EM. Increasing implementation
546 and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement.
547 The European respiratory journal. 2016;47(5):1336-41. Epub 2016/05/02. doi:
548 10.1183/13993003.02151-2015. PubMed PMID: 27132269.
549 29. Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, et al. RNA based mNGS approach identifies a
550 novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak.
551 Emerging Microbes and Infections. 2020;9(1):313-9. PubMed PMID: 2004238813.
552 30. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
553 characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
554 study. Lancet. 2020;395(10223):507-13. Epub 2020/02/03. doi: 10.1016/s0140-6736(20)30211-
555 7. PubMed PMID: 32007143; PubMed Central PMCID: PMCPMC7135076.

556 31. Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N, et al. Factors Associated With Mental Health
557 Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA network
558 open. 2020;3(3):e203976. Epub 2020/03/24. doi: 10.1001/jamanetworkopen.2020.3976.
559 PubMed PMID: 32202646; PubMed Central PMCID: PMCPMC7090843.
560 32. Mak IWC, Chu CM, Pan PC, Yiu MGC, Chan VL. Long-term psychiatric morbidities among
561 SARS survivors. General hospital psychiatry. 2009;31(4):318-26.
562 33. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
563 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.
564 2020;395(10229):1054-62. Epub 2020/03/15. doi: 10.1016/S0140-6736(20)30566-3. PubMed
565 PMID: 32171076.
566 34. Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. Comorbidity and its
567 impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory
568 Journal. 2020;55(5).
569 35. WHO. International Classification of Functioning, Disability, and Health. Geneva: WHO
570 Press; 2001.
571 36. Armitage R, Nellums LB. The COVID-19 response must be disability inclusive. The Lancet
572 Public Health. 2020;5(5):e257.
573 37. WHO. Disability considerations during the COVID-19 outbreak: World Health
574 Organization; 2020 [cited 2020 Aug 10]. Available from:
575 https://apps.who.int/iris/bitstream/handle/10665/332015/WHO-2019-nCov-Disability-2020.1-
576 eng.pdf.

577 38. Solomon MZ, Wynia MK, Gostin LO. Covid-19 crisis triage—optimizing health outcomes
578 and disability rights. New England Journal of Medicine. 2020.
579 39. Giummarra MJ, Lennox A, Dali G, Costa B, Gabbe BJ. Early psychological interventions for
580 posttraumatic stress, depression and anxiety after traumatic injury: A systematic review and
581 meta-analysis. Clinical psychology review. 2018;62:11-36. Epub 2018/05/14. doi:
582 10.1016/j.cpr.2018.05.001. PubMed PMID: 29754102.
583 40. Zhang L, Hu W, Cai Z, Liu J, Wu J, Deng Y, et al. Early mobilization of critically ill patients
584 in the intensive care unit: A systematic review and meta-analysis. PLoS One.
585 2019;14(10):e0223185. Epub 2019/10/04. doi: 10.1371/journal.pone.0223185. PubMed PMID:
586 31581205; PubMed Central PMCID: PMC6776357.
587 41. Xiao Y, Zhao K, Ma ZX, Li X, Qiu YP. Integrated medical rehabilitation delivery in China.
588 Chronic diseases and translational medicine. 2017;3(2):75-81. Epub 2017/10/25. doi:
589 10.1016/j.cdtm.2017.02.003. PubMed PMID: 29063059; PubMed Central PMCID: PMC5627700.

590

591

Supporting information

Table S1. Outcome: One or more IADL problems (Lawton IADL scale, at least one item endorsed)[&]. [&] n= 431 for adjusted model and unadjusted model for age, n= 432 for all other models. RR = Risk Ratio. CI = Confidence Interval.

Table S2. Outcome: At least moderate ADL dependence (Barthel Index, < 75)[&]. [&]n= 431 for adjusted model and unadjusted model for age, n= 432 for all other models. RR = Risk Ratio. CI = Confidence Interval.

Table S3. Outcome: Anxiety (Zung's self-reported anxiety scale, raw score < 40)[&]. [&]n=407 for adjusted model and n=407 for unadjusted model for length of stay, n= 431 for unadjusted model for age, n= 432 for all other models. RR = Risk Ratio. CI = Confidence Interval.

1. Presence of IADL limitations (at least one)



2. ADL dependence (at least moderate)




Gender
female
male
Age, years
< 50
50-60
> 60
Province
other province
Hubei
Ethnicity
Han
Tibetan
Current smoking
no
yes
Comorbid condition
none
one
multi
Disease severity
non-severe
severe
Symptoms, number
<= 1
>1
Infection scope
unilateral
bilateral
Length of hospital stay
1-14
>14
0
1
2
3
4
5
6
7
Risk ratio and 95% CIs
Model
unadjusted
adjusted


Predicted number of IADL problems
0
1
2
3
4
5
6
< 50
50-60
> 60
Age, years
Disease severity
non-severe
severe